Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) as Early Predictors of Biologic Response in Severe Asthma

Drew Davies,1 Joseph W Lanario,2,3 Michael E Hyland,2 Matthew Masoli1,3 1Department of Respiratory Medicine, Royal Devon and Exeter Hospital, University of Exeter, Exeter, UK; 2Faculty of Health, University of Plymouth, Plymouth, UK; 3University of Exeter, Royal Devon and Exeter Hospital, Exeter, UKCorrespondence: Joseph W Lanario, Plymouth Science Park, Room N10, ITTC Building, Plymouth, Devon, PL6 8BX, UK, Tel +44 01752 764 403, Email [email protected]: Biologic therapy in asthma can be life-changing and affect health-related quality of life, but symptoms are rarely used in the assessment of response.Aim: To examine the change in health-related quality of life and asthma control between starting a biologic and assessment of biologic response, assessing whether this change can provide early prediction of eventual clinical response at 12 months.Methods: A service evaluation of severe asthmatics initiating a biologic at the Royal Devon NHS trust between 2019 and 22. Health-Related Quality of Life (Severe Asthma Questionnaire) and asthma control (Asthma Control Questionnaire-6) was captured at baseline, 8 weeks, 16 weeks and 12 months. Patients were classified as responder or non-responder using NICE Criteria for biologic response. Independent samples t-tests were used to determine statistical difference in change from baseline patient reported outcome measure scores between responder and non-responders.Results: One hundred and eight initiations (103 patients) of biologic therapy were included. At 8 weeks and 16 weeks, responders had greater improvement in Severe Asthma Questionnaire & Severe Asthma Questionnaire Global compared to non-responders (p< 0.05). Improvement in Asthma Control Questionnaire only achieved significance between all-responders and non-responders at 16 weeks (p< 0.05).Conclusion: This study provides evidence of the early and sustained improvement in health-related quality of life and symptoms after starting biologic therapy. The findings support the use of the Severe Asthma Questionnaire and the Asthma Control Questionnaire as per the Core Outcome Measures Sets for Severe Asthma (COMSA). We have shown that health-related quality of life and asthma control can assist earlier assessment of response and non-response to biologics.Keywords: severe asthma, quality of life, patient reported outcomes, patient-centred, biologics

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-05-01
Primary Topic
Marine Biology and Environmental Chemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) as Early Predictors of Biologic Response in Severe Asthma

SHILAP Revista de lepidopterología
Marine Biology and Environmental Chemistry
article

Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) as Early Predictors of Biologic Response in Severe Asthma

article en

Abstract

Drew Davies,1 Joseph W Lanario,2,3 Michael E Hyland,2 Matthew Masoli1,3 1Department of Respiratory Medicine, Royal Devon and Exeter Hospital, University of Exeter, Exeter, UK; 2Faculty of Health, University of Plymouth, Plymouth, UK; 3University of Exeter, Royal Devon and Exeter Hospital, Exeter, UKCorrespondence: Joseph W Lanario, Plymouth Science Park, Room N10, ITTC Building, Plymouth, Devon, PL6 8BX, UK, Tel +44 01752 764 403, Email [email protected]: Biologic therapy in asthma can be life-changing and affect health-related quality of life, but symptoms are rarely used in the assessment of response.Aim: To examine the change in health-related quality of life and asthma control between starting a biologic and assessment of biologic response, assessing whether this change can provide early prediction of eventual clinical response at 12 months.Methods: A service evaluation of severe asthmatics initiating a biologic at the Royal Devon NHS trust between 2019 and 22. Health-Related Quality of Life (Severe Asthma Questionnaire) and asthma control (Asthma Control Questionnaire-6) was captured at baseline, 8 weeks, 16 weeks and 12 months. Patients were classified as responder or non-responder using NICE Criteria for biologic response. Independent samples t-tests were used to determine statistical difference in change from baseline patient reported outcome measure scores between responder and non-responders.Results: One hundred and eight initiations (103 patients) of biologic therapy were included. At 8 weeks and 16 weeks, responders had greater improvement in Severe Asthma Questionnaire & Severe Asthma Questionnaire Global compared to non-responders (p< 0.05). Improvement in Asthma Control Questionnaire only achieved significance between all-responders and non-responders at 16 weeks (p< 0.05).Conclusion: This study provides evidence of the early and sustained improvement in health-related quality of life and symptoms after starting biologic therapy. The findings support the use of the Severe Asthma Questionnaire and the Asthma Control Questionnaire as per the Core Outcome Measures Sets for Severe Asthma (COMSA). We have shown that health-related quality of life and asthma control can assist earlier assessment of response and non-response to biologics.Keywords: severe asthma, quality of life, patient reported outcomes, patient-centred, biologics

SHILAP Revista de lepidopterología
Faculty of Public Health (GB)
Openalex Percentile: Top 45%
Marine Biology and Environmental Chemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.